Granulomatosis with polyangiitis – therapeutic challenge
The antineutrophil cytoplasmic antibody (ANCA) associated vasculitides (AAV) are a group of primary vasculitides that affect predominantly small- to medium-sized blood vessels. The pathology of granulomatosis with polyangiitis (GPA) typically features a granulomatous and sometimes necrotizing vascul...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Termedia Publishing House
2016-02-01
|
Series: | Rheumatology |
Subjects: | |
Online Access: | http://www.termedia.pl/Granulomatosis-with-polyangiitis-therapeutic-challenge,18,26874,1,1.html |
id |
doaj-ebd77f874e5a4a2ab0bfdfccb7739469 |
---|---|
record_format |
Article |
spelling |
doaj-ebd77f874e5a4a2ab0bfdfccb77394692020-11-24T23:07:04ZengTermedia Publishing HouseRheumatology0034-62332084-98342016-02-0153634535110.5114/reum.2015.5764226874Granulomatosis with polyangiitis – therapeutic challengeDorota SzydlarskaMałgorzata WisłowskaThe antineutrophil cytoplasmic antibody (ANCA) associated vasculitides (AAV) are a group of primary vasculitides that affect predominantly small- to medium-sized blood vessels. The pathology of granulomatosis with polyangiitis (GPA) typically features a granulomatous and sometimes necrotizing vasculitis targeting predominantly the respiratory tract and kidneys, including necrotizing granulomatous inflammation. The diagnosis can be delayed due to the nonspecific nature of the symptoms. Cyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis for years. Recently, the monoclonal antibody rituximab was approved for the treatment of GPA, providing an alternative to cyclophosphamide for induction therapy of AAV. In the present case study we used azathioprine as the maintenance drug. However, because of relapse we tried mycophenolate mofetil (MMF) as a second-line drug successfully. This case confirms that MMF is not only well tolerated but also effective in GPA to maintain remission.http://www.termedia.pl/Granulomatosis-with-polyangiitis-therapeutic-challenge,18,26874,1,1.htmlmycophenolate mofetil azathioprine polyangiitis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Dorota Szydlarska Małgorzata Wisłowska |
spellingShingle |
Dorota Szydlarska Małgorzata Wisłowska Granulomatosis with polyangiitis – therapeutic challenge Rheumatology mycophenolate mofetil azathioprine polyangiitis |
author_facet |
Dorota Szydlarska Małgorzata Wisłowska |
author_sort |
Dorota Szydlarska |
title |
Granulomatosis with polyangiitis – therapeutic challenge |
title_short |
Granulomatosis with polyangiitis – therapeutic challenge |
title_full |
Granulomatosis with polyangiitis – therapeutic challenge |
title_fullStr |
Granulomatosis with polyangiitis – therapeutic challenge |
title_full_unstemmed |
Granulomatosis with polyangiitis – therapeutic challenge |
title_sort |
granulomatosis with polyangiitis – therapeutic challenge |
publisher |
Termedia Publishing House |
series |
Rheumatology |
issn |
0034-6233 2084-9834 |
publishDate |
2016-02-01 |
description |
The antineutrophil cytoplasmic antibody (ANCA) associated vasculitides (AAV) are a group of primary vasculitides that affect predominantly small- to medium-sized blood vessels. The pathology of granulomatosis with polyangiitis (GPA) typically features a granulomatous and sometimes necrotizing vasculitis targeting predominantly the respiratory tract and kidneys, including necrotizing granulomatous inflammation. The diagnosis can be delayed due to the nonspecific nature of the symptoms. Cyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis for years. Recently, the monoclonal antibody rituximab was approved for the treatment of GPA, providing an alternative to cyclophosphamide for induction therapy of AAV. In the present case study we used azathioprine as the maintenance drug. However, because of relapse we tried mycophenolate mofetil (MMF) as a second-line drug successfully. This case confirms that MMF is not only well tolerated but also effective in GPA to maintain remission. |
topic |
mycophenolate mofetil azathioprine polyangiitis |
url |
http://www.termedia.pl/Granulomatosis-with-polyangiitis-therapeutic-challenge,18,26874,1,1.html |
work_keys_str_mv |
AT dorotaszydlarska granulomatosiswithpolyangiitistherapeuticchallenge AT małgorzatawisłowska granulomatosiswithpolyangiitistherapeuticchallenge |
_version_ |
1725620298937532416 |